474.20CHF-0.82%Mkt Cap: 33.12B CHFP/E: 36.51Last update: 2026-05-13
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)36.51
P/E (Forward)21.53
PEG1.39
P/B4.14
P/S5.02
EV/EBITDA17.22
EV/Revenue5.63
EPS (TTM)13.00
EPS (Forward)21.81
Cash Flow & Leverage
FCF Yield-5.43%
FCF Margin-27.54%
Operating CF1.16B CHF
CapEx (TTM)1.37B CHF
Net Debt/EBITDA1.85
Net Debt3.96B CHF
Technical
SMA 50496.05 (-4.4%)
SMA 200531.79 (-10.8%)
Beta0.82
S&P 52W Chg24.23%
Avg Vol (30d)176.56K
Avg Vol (10d)173.55K
Technical Indicators
RSI (14)38.4
MACD-7.4725
MACD Signal-5.8326
MACD Hist.-1.6399
BB Upper539.87 CHF
BB Middle496.22 CHF
BB Lower452.57 CHF
BB Width17.59%
ATR (14)12.18 CHF
Vol Ratio (20d)0.80x
52W Range
454.6014% of range594.80
52W High594.80 CHF
52W Low454.60 CHF
Profitability
Gross Margin35.35%
EBITDA Margin32.72%
Profit Margin-4.21%
Oper. Margin21.39%
ROE-3.48%
ROA-1.54%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.57
Current Ratio1.89
Quick Ratio0.62
Book Value/Sh113.30 CHF
Cash/Share10.29 CHF
Dividends
Fwd Div Rate5.000 CHF
Trail. Div Rate5.000 CHF
Div. Yield1.07%
5Y Avg Yield0.66%
Payout Ratio30.77%
Ex-Div DateMay 12, 2026
Pay DateMay 15, 2025
Ownership
Shares Out.69.84M
Float69.81M
Insiders0.09%
Institutions60.60%
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)669.30 CHF
Target Range550.00 CHF – 815.00 CHF
# Analysts23
Company
Market Cap33.12B CHF
Enterprise Value36.80B CHF
Revenue (TTM)6.53B CHF
Gross Profit2.31B CHF
Net Income (TTM)-275.00M CHF
Revenue/Share93.27 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees20.0K
Last Price474.20 CHF
CountryCH
SectorHealthcare
IndustryDiagnostics & Research
ISIN—